Cover Image
市場調查報告書

平滑肌肉瘤:開發平台分析

Leiomyosarcoma - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 247798
出版日期 內容資訊 英文 144 Pages
訂單完成後即時交付
價格
Back to Top
平滑肌肉瘤:開發平台分析 Leiomyosarcoma - Pipeline Review, H1 2017
出版日期: 2017年03月31日 內容資訊: 英文 144 Pages
簡介

平滑肌肌瘤,是源自子宮和腸胃等軟組織的典型平滑肌細胞的惡性軟組織肉瘤。症狀有清楚的包塊及瘤,會壓迫神經和肌肉造成疼痛。還有若在腹部和消化管有腫瘤,會成為腸胃的障礙物,引起消化道出血。 發病的原因是年齡,暴露於化學物質,暴露於放射線等。治療有化療和放射治療,外科手術。

由於本報告提供平滑肌肌瘤的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 調查範圍
  • 平滑肌肉瘤概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

平滑肌肉瘤:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥開發作的企業

  • Advenchen Laboratories, LLC
  • BeiGene, Ltd.
  • Cell Medica Limited
  • Karyopharm Therapeutics, Inc.
  • Merck & Co., Inc.
  • Mirati Therapeutics Inc.
  • Novartis AG
  • Vicore Pharma AB

治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AL-3818
  • BGB-290
  • C-21
  • 以腫瘤學、感染疾病的 LMP-1/LMP-2 為標的細胞免疫療法 CMD-003
  • Everolimus
  • mocetinostat
  • NOV-110501
  • Pazopanib鹽酸鹽
  • pembrolizumab
  • selinexor

平滑肌肉瘤:最近的開發平台趨勢

平滑肌肉瘤:暫停中的計劃

開發中止的產品

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9101IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leiomyosarcoma - Pipeline Review, H1 2017, provides an overview of the Leiomyosarcoma (Oncology) pipeline landscape.

Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. Symptoms include a noticeable lump or swelling, pain, if it presses on nerves or muscles and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure and radiation exposure. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Leiomyosarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Leiomyosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leiomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Leiomyosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Leiomyosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Leiomyosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Leiomyosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Leiomyosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Leiomyosarcoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Leiomyosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Leiomyosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Leiomyosarcoma - Overview
    • Leiomyosarcoma - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Leiomyosarcoma - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Leiomyosarcoma - Companies Involved in Therapeutics Development
    • Advenchen Laboratories LLC
    • BeiGene Ltd
    • Cell Medica Ltd
    • Karyopharm Therapeutics Inc
    • Merck & Co Inc
    • Merck KGaA
    • Mirati Therapeutics Inc
    • Novartis AG
    • Pfizer Inc
    • Vicore Pharma AB
    • Yooyoung Pharmaceutical Co Ltd
  • Leiomyosarcoma - Drug Profiles
    • AL-3818 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • avelumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • axitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • baltaleucel-T - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BGB-290 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-21 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mocetinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pembrolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • selinexor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YYB-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Leiomyosarcoma - Dormant Projects
  • Leiomyosarcoma - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Leiomyosarcoma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Leiomyosarcoma - Pipeline by Advenchen Laboratories LLC, H1 2017
  • Leiomyosarcoma - Pipeline by BeiGene Ltd, H1 2017
  • Leiomyosarcoma - Pipeline by Cell Medica Ltd, H1 2017
  • Leiomyosarcoma - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Leiomyosarcoma - Pipeline by Merck & Co Inc, H1 2017
  • Leiomyosarcoma - Pipeline by Merck KGaA, H1 2017
  • Leiomyosarcoma - Pipeline by Mirati Therapeutics Inc, H1 2017
  • Leiomyosarcoma - Pipeline by Novartis AG, H1 2017
  • Leiomyosarcoma - Pipeline by Pfizer Inc, H1 2017
  • Leiomyosarcoma - Pipeline by Vicore Pharma AB, H1 2017
  • Leiomyosarcoma - Pipeline by Yooyoung Pharmaceutical Co Ltd, H1 2017
  • Leiomyosarcoma - Dormant Projects, H1 2017
  • Leiomyosarcoma - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Leiomyosarcoma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top